Our editorials criticizing the Food and Drug Administration for torpedoing promising treatments must be hitting an intracranial nerve. Proof of their potency: Commissioner Marty Makary and his deputy Vinay Prasad devoted much of a recent FDA podcast to mischaracterizing them.
We’re flattered by the attention, but the spin doctors cried fake news rather than address the substantive arguments. If they really want to prove they’re not impeding life-saving treatments, they’ll approve
Replenishment’s RP1 immunotherapy for metastatic melanoma, which the agency rejected this summer.
Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
